Login
Super Investors Ally Bridge Group (NY) LLC
AB

Ally Bridge Group (NY) LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$76M
Positions
18
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (24 quarters reported)

$584M $76M
Q4 20 Q1 22 Q2 23 Q3 24 Q4 25 Q3 26

$584M in Q4 2020 → $76M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Definium Therapeutics Inc Call 20.0% Unchanged 400,000 $15.2M
AS Abivax Sa Call 16.3% Unchanged 125,000 $12.4M
Edgewise Therapeutics Inc 9.9% Added 123% 185,430 $7.53M
Promis Neurosciences Inc 8.9% Unchanged 620,319 $6.73M
Minerva Neurosciences Inc 7.3% Trimmed 24% 1,655,500 $5.55M
Amylyx Pharmaceuticals Inc 7.0% New 182,000 $5.3M
Shattuck Labs Inc 5.6% New 625,190 $4.26M
Obsidian Therapeutics Inc 5.5% New 302,449 $4.15M
Alumis Inc Call 3.9% New 400,000 $2.96M
An2 Therapeutics Inc 3.7% Unchanged 526,315 $2.8M
Eupraxia Pharmaceuticals Inc 2.8% Trimmed 8.3% 231,122 $2.1M
Compass Therapeutics Inc Call 2.7% New 2,000,000 $2.08M
Avalo Therapeutics Inc 2.7% Trimmed 10% 134,429 $2.06M
IS Inventiva Sa 1.1% Trimmed 64% 227,250 $839K
V Vogenx Inc 1.0% New 32,701 $745K
Traws Pharma Inc 0.6% Unchanged 786,236 $467K
Perspective Therapeutics Inc 0.6% Trimmed 78% 163,634 $450K
Assembly Biosciences Inc 0.6% Trimmed 87% 18,298 $430K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
First Tracks Biotherapeutics Exited −284,287 −$5.72M —
Amylyx Pharmaceuticals Inc New +182,000 +$5.3M 7.0%
Shattuck Labs Inc New +625,190 +$4.26M 5.6%
Obsidian Therapeutics Inc New +302,449 +$4.15M 5.5%
Edgewise Therapeutics Inc Added +102,130 +$4.15M 9.9%
Axsome Therapeutics Inc Exited −16,493 −$4.04M —
Whitehawk Therapeutics Inc Exited −817,939 −$3.75M —
Climb Bio Inc Exited −249,172 −$3.25M —
Kura Oncology Inc Exited −290,000 −$3.18M —
Alumis Inc New +400,000 +$2.96M 3.9%

Showing the 10 largest of 26 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Definium Therapeutics Inc New +400,000 +$18.8M 16.6%
AS Abivax Sa New +125,000 +$16.7M 14.7%
PP Praxis Precision Medicines I Exited −32,810 −$10.6M —
Soleno Therapeutics Inc Exited −200,000 −$6.7M —
Soleno Therapeutics Inc Exited −200,000 −$6.7M —
Ovid Therapeutics Inc Trimmed −2,193,898 −$5.9M 1.5%
Compass Pathways PLC Exited −1,045,000 −$5.78M —
First Tracks Biotherapeutics New +284,287 +$5.72M 5.1%
Tarsus Pharmaceuticals Inc Exited −80,859 −$5.67M —
Compass Therapeutics Inc Exited −1,000,000 −$5.29M —

Showing the 10 largest of 37 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 18, 2026

Company Action Shares changed Value of change % of portfolio
Compass Pathways PLC Exited −1,100,000 −$7.59M —
Replimune Group Inc Trimmed −953,100 −$7.29M 1.5%
AB Atai Beckley Nv Exited −1,713,105 −$7.01M —
Soleno Therapeutics Inc New +200,000 +$6.7M 5.4%
Edgewise Therapeutics Inc Exited −250,000 −$6.2M —
Compass Pathways PLC New +1,045,000 +$5.78M 4.7%
Tarsus Pharmaceuticals Inc New +80,859 +$5.67M 4.6%
Compass Therapeutics Inc New +1,000,000 +$5.29M 4.3%
Cytomx Therapeutics Inc. New +900,000 +$4.23M 3.4%
IS Inventiva Sa Trimmed −754,700 −$4.19M 3.3%

Showing the 10 largest of 30 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Replimune Group Inc Trimmed −2,400,000 −$23.3M 12.2%
Soleno Therapeutics Inc Exited −250,000 −$16.9M —
Madrigal Pharmaceuticals Inc Exited −32,662 −$15M —
AP Ascendis Pharma A/s - ADR Exited −51,080 −$10.2M —
AS Abivax Sa New +70,000 +$9.44M 9.8%
Lenz Therapeutics Inc Exited −175,363 −$8.17M —
Taysha Gene Therapies Inc Trimmed −1,440,980 −$7.93M 2.6%
IS Inventiva Sa New +1,500,000 +$6.98M 7.3%
Minerva Neurosciences Inc New +1,655,500 +$6.66M 6.9%
Soleno Therapeutics Inc Trimmed −134,454 −$6.23M 8.1%

Showing the 10 largest of 33 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Soleno Therapeutics Inc New +250,000 +$16.9M 10.3%
Verona Pharma PLC Exited −160,701 −$15.2M —
Replimune Group Inc New +3,600,000 +$15.1M 9.2%
Madrigal Pharmaceuticals Inc New +32,662 +$15M 9.1%
AB Atai Beckley Nv New +2,287,005 +$12.1M 7.4%
AP Ascendis Pharma A/s - ADR New +51,080 +$10.2M 6.2%
Soleno Therapeutics Inc Added +123,664 +$8.36M 12.5%
Lenz Therapeutics Inc Trimmed −167,959 −$7.82M 5.0%
Merus N V Exited −140,208 −$7.37M —
Compass Pathways PLC New +1,145,700 +$6.56M 4.0%

Showing the 10 largest of 37 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Springworks Therapeutics Inc Exited −281,139 −$12.4M —
Lenz Therapeutics Inc New +343,322 +$10.1M 8.4%
Axsome Therapeutics Inc Exited −72,113 −$8.41M —
Blueprint Medicines Corp Exited −74,192 −$6.57M —
Axsome Therapeutics Inc Exited −50,000 −$5.83M —
UP Ultragenyx Pharmaceutical In New +1,600 +$5.82M 4.8%
Oric Pharmaceuticals Inc New +485,629 +$4.93M 4.1%
Replimune Group Inc New +528,491 +$4.91M 4.1%
Soleno Therapeutics Inc Added +58,370 +$4.89M 12.5%
Trevi Therapeutics Inc Exited −686,219 −$4.32M —

Showing the 10 largest of 36 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
IT Intra-cellular Therapies Inc Exited −147,750 −$12.3M —
Springworks Therapeutics Inc Added +226,447 +$9.99M 11.2%
VP Verona Pharma PLC - ADR New +139,067 +$8.83M 8.0%
Axsome Therapeutics Inc New +50,000 +$5.83M 5.3%
Alumis Inc Exited −445,259 −$3.5M —
Jasper Therapeutics Inc Exited −122,424 −$2.62M —
Eyepoint Pharmaceuticals Inc Exited −348,000 −$2.59M —
89bio Inc Exited −317,833 −$2.49M —
Soleno Therapeutics Inc Added +32,820 +$2.34M 7.8%
Tectonic Therapeutic Inc New +132,222 +$2.34M 2.1%

Showing the 10 largest of 33 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
IT Intra-cellular Therapies Inc New +147,750 +$12.3M 10.6%
Sarepta Therapeutics Inc Exited −72,000 −$8.99M —
Tarsus Pharmaceuticals Inc Trimmed −148,754 −$8.24M 8.2%
LP Longboard Pharmaceuticals In Exited −240,892 −$8.03M —
Revolution Medicines Inc Exited −163,500 −$7.41M —
Springworks Therapeutics Inc Trimmed −173,008 −$6.25M 1.7%
Jasper Therapeutics Inc Trimmed −277,042 −$5.92M 2.2%
Kura Oncology Inc Exited −294,081 −$5.75M —
Axsome Therapeutics Inc New +66,661 +$5.64M 4.8%
Applied Therapeutics Inc Exited −618,332 −$5.26M —

Showing the 10 largest of 37 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support